Share This:
https://ntp.niehs.nih.gov/go/37073

Target Organs and Levels of Evidence for TR-569

Toxicology and Carcinogenesis Study of 3'-Azido-3'-Deoxythymidine (AZT) (CASRN 30516-87-1) in B6C3F1 Mice (Transplacental Exposure Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
(AZT)
04/05/2011 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
0, 80, 160, or 240 mg/kg
National Center for Toxicological Research

Levels of Evidence

Male Mice: No Evidence
Female Mice: Equivocal Evidence
Type Organ/Tissue (Lesion)
May Have Been Related
  • Thyroid Gland Follicular Cell: adenoma 0/59 1/46 0/46 3/47; adenoma or carcinoma 0/59 1/46 0/46 4/47 -- AZT
  • Skin: (subcutaneous tissue): fibrosarcoma or sarcoma 2/63 0/46 4/47 5/48 -- AZT


Toxicology and Carcinogenesis Study of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT) and Lamivudine (3TC) (CASRN 30516-87-1, 134678-17-4) in B6C3F1 Mice (Transplacental Exposure Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
(AZT/3TC)
04/05/2011 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
0, 80/40, 160/80, or 240/120 mg/kg
National Center for Toxicological Research

Levels of Evidence

Male Mice: No Evidence
Female Mice: Equivocal Evidence
Type Organ/Tissue (Lesion)
May Have Been Related
  • Lung: alveolar/bronchiolar adenoma 2/62 1/48 3/50 6/48 -- AZT/3TC


Toxicology and Carcinogenesis Study of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRN 30516-87-1, 134678-17-4, 129618-40-2) in B6C3F1 Mice (Transplacental Exposure Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
(AZT/3TC/NVP)
04/05/2011 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
0, 80/40/56, 160/80/112, or 240/120/168 mg/kg
National Center for Toxicological Research

Levels of Evidence

Male Mice: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Skin: (subcutaneous tissue): fibroma, fibrous, histiocytoma, or fibrosarcoma 2/65 2/47 7/48 12/48 -- AZT/3TC/NVP

Female Mice: Equivocal Evidence
Type Organ/Tissue (Lesion)
May Have Been Related
  • Skin: (subcutaneous tissue): fibrosarcoma 1/63 0/47 7/47 0/49 -- AZT/3TC/NVP


Toxicology and Carcinogenesis Study of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nelfinavir Mesylate (NFV) (CASRN 30516-87-1, 134678-17-4, 159989-65-8) in B6C3F1 Mice (Transplacental Exposure Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
(AZT/3TC/NFV)
04/05/2011 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
0, 80/40/336, 160/80/672, or 240/120/1,008 mg/kg
National Center for Toxicological Research

Levels of Evidence

Male Mice: No Evidence
Female Mice: No Evidence